Slovenia‘s national HIV PrEP programme: Evaluation of real-world implementation

Abstract

Background

The aim of our study was to evaluate real-world implementation of Slovenia’s national HIV PrEP programme, which is fully covered by our national health insurance.

Methods

In retrospective cohort study we analysed the data from all men who have sex with men (MSM) who were enrolled in PrEP programme of our clinic between 1 January 2022 and 31 December 2022.

Results

A total of 190 MSM with an average age of 36.7 years were included in our analysis. 151 (79.5%) decided for event-driven PrEP and 39 (20.5%) opted for daily PrEP. Self-reported adherence was 95%. Among eligibility criteria, unprotected sex was the most common one, followed by one or more STIs in the past, use of chemsex and use of HIV post-exposure prophylaxis in the past. No new cases of HIV infection and no significant deterioration of kidney or liver function were observed during the follow-up. Sixty-seven episodes of STIs were diagnosed and treated. Gonorrhea (32), chlamydia (14), and Mpox (10) were the most common ones.

Conclusions

PrEP was successfully implemented into everyday clinical practice, proving to be both safe and effective. High number of diagnosed STIs suggests that the PrEP programme, combined with STI screening and vaccination, provides a strong public health impact among MSM in Slovenia.

Keywords

Europe antiretroviral therapy prevention human immunodeficiency virus (HIV)viral disease

Get full access to this article

View all access options for this article.

References

Grant

Lama

Anderson

, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587–2599.

McCormack

Dunn

Desai

, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016; 387(10013): 53–60.

Molina

J-M

Capitant

Spire

, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med 2015; 373(23): 2237–2246.

EACS.EACS . Guidelines. 12th ed, 2023, https://www.eacsociety.org/guidelines/eacs-guidelines.

Spinner

Boesecke

Zink

, et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection 2016; 44(2): 151–158.

ViiV Press Release . European Medicines Agency validates ViiV Healthcare’s marketing authorisation application for cabotegravir long-acting injectable for HIV Prevention. https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2022/october/european-medicines-agency-validates-viiv-healthcareEACS.guidelines

Traeger

Guy

Asselin

, et al. Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data. Lancet Infect Dis 2022; 22(8): 1231–1241.

Gafos

Horne

Nutland

, et al. The context of sexual risk behaviour among men who have sex with men seeking PrEP, and the impact of PrEP on sexual behaviour. AIDS Behav 2019; 23: 1708–1720.

Werner

Gaskins

Nast

, et al. Incidence of sexually transmitted infections in men who have sex with men and who are at substantial risk of HIV infection – a meta-analysis of data from trials and observational studies of HIV pre-exposure prophylaxis. Mugo PM. PLoS One 2018; 13(12): e0208107.

10.

Gibas

van den Berg

Powell

, et al. Drug resistance during HIV pre-exposure prophylaxis. Drugs 2019; 79: 609–619.

11.

Spinner

Boesecke

Zink

, et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection 2015; 44(2): 151–158.

12.

Okužba s HIV v Sloveniji: Podatki o prijavljenih primerih do vključno 20. november 2022. Ljubljana: Nacionalni inštitut za javno zdravje, 2022. https://nijz.si/wp-content/uploads/2022/11/okuzba_s_hiv_v_si_do_vkljucno_20.11.2022_-_sda.pdf.

13.

WHO Regional Office for Europe, European Centre for Disease Prevention and Control . HIV/AIDS surveillance in Europe 2022 – 2021 data. Copenhagen: WHO Regional Office for Europe, 2022. https://www.ecdc.europa.eu/sites/default/files/documents/2022-Annual_HIV_Report_final.pdf.

14.

Pečavar

Turel

, et al. Pre-exposure prophylaxis for HIV with oral tenofovir disoproxil fumarate/emtricitabine in men who have sex with men: Slovenian national demonstration project. Int J STD AIDS 2021; 0(0): 1–6.

15.

Noret

Balavoine

Pintado

, et al. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France. AIDS 2018; 32: 2161–2169.

16.

Hoornenborg

Coyer

Achterbergh

RCA

, et al. Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam (H-TEAM) Initiative. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven pre-exposure prophylaxis in AMPrEP: 2 year results from a demonstration study. Lancet HIV 2019; 6(7): e447–e455.

17.

Jongen

Reyniers

Ypma

, et al. Choosing event-driven and daily HIV pre-exposure prophylaxis - data from two European PrEP demonstration projects among men who have sex with men. J Int AIDS Soc 2021; 24(8): e25768.

18.

Klavs

Kosmač

Kasteli

, et al. Spolno prenesene okužbe v Sloveniji: letno poročilo 2020. Ljubljana: Nacionalni inštitut za javno zdravje, 2020. https://nijz.si/wp-content/uploads/2021/05/spo_2020_koncno.pdf.

19.

Ugarte

de la Mora

García

, et al. Evolution of risk behaviors, sexually transmitted infections and PrEP care continuum in a hospital-based PrEP program in Barcelona, Spain: a descriptive study of the first 2 Years’ experience. Infect Dis Ther 2022; 12(2): 425–442.

20.

Schmidt

Bourne

Weatherburn

, et al. Illicit drug use among gay and bisexual men in 44 cities: findings from the European MSM Internet Survey (EMIS). Int J Drug Policy 2016; 38: 4–12.

21.

Jenness

Weiss

Goodreau

, et al. Incidence of gonorrhea and Chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study. Clin Infect Dis 2017; 65(5): 712–718.